NCT06040424View on ClinicalTrials.gov

Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
COPD
Interventions
COMBINATION_PRODUCT

Ipratropium / Levosalbutamol Fixed Dose Combination

New combination test treatment

DRUG

Ipratropium + Levosalbutamol Free Dose Combination

Free combination control treatment

Trial Locations (1)

Unknown

Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul

All Listed Sponsors
lead

Neutec Ar-Ge San ve Tic A.Ş

INDUSTRY

NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients | Biotech Hunter | Biotech Hunter